CL2014001073A1 - Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy. - Google Patents
Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy.Info
- Publication number
- CL2014001073A1 CL2014001073A1 CL2014001073A CL2014001073A CL2014001073A1 CL 2014001073 A1 CL2014001073 A1 CL 2014001073A1 CL 2014001073 A CL2014001073 A CL 2014001073A CL 2014001073 A CL2014001073 A CL 2014001073A CL 2014001073 A1 CL2014001073 A1 CL 2014001073A1
- Authority
- CL
- Chile
- Prior art keywords
- lewy bodies
- synuclein
- reduce
- humanized antibodies
- detect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553131P | 2011-10-28 | 2011-10-28 | |
| US201261711208P | 2012-10-08 | 2012-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001073A1 true CL2014001073A1 (es) | 2014-12-19 |
Family
ID=48168610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001073A CL2014001073A1 (es) | 2011-10-28 | 2014-04-25 | Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy. |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US8609820B2 (es) |
| EP (2) | EP2771031B1 (es) |
| JP (4) | JP5775974B2 (es) |
| KR (1) | KR101600733B1 (es) |
| CN (2) | CN107880123A (es) |
| AU (3) | AU2012328530A1 (es) |
| BR (1) | BR112014010198B1 (es) |
| CA (1) | CA2853531C (es) |
| CL (1) | CL2014001073A1 (es) |
| CO (1) | CO7020875A2 (es) |
| CY (1) | CY1120398T1 (es) |
| DK (2) | DK3378535T5 (es) |
| ES (2) | ES2669395T3 (es) |
| FI (1) | FI3378535T3 (es) |
| HK (1) | HK1252895A1 (es) |
| HR (2) | HRP20180728T1 (es) |
| HU (2) | HUE037811T2 (es) |
| IL (2) | IL232264B (es) |
| LT (2) | LT2771031T (es) |
| MX (2) | MX370234B (es) |
| MY (1) | MY165038A (es) |
| PE (1) | PE20141568A1 (es) |
| PH (1) | PH12014500938B1 (es) |
| PL (2) | PL2771031T3 (es) |
| PT (2) | PT2771031T (es) |
| RS (2) | RS63930B1 (es) |
| RU (1) | RU2743738C2 (es) |
| SG (1) | SG11201401857WA (es) |
| SI (2) | SI2771031T1 (es) |
| SM (2) | SMT202300048T1 (es) |
| UA (1) | UA116194C2 (es) |
| WO (1) | WO2013063516A1 (es) |
| ZA (1) | ZA201403864B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
| CN108517010A (zh) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | 识别α-突触核蛋白的人源化抗体 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| EP3071974A2 (en) * | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| WO2017207739A1 (en) | 2016-06-02 | 2017-12-07 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
| US20180328943A1 (en) * | 2016-09-30 | 2018-11-15 | Enzo Biochem, Inc. | Immunomodulatory compositions and methods of use thereof |
| US10889635B2 (en) * | 2016-11-15 | 2021-01-12 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| JP2020501132A (ja) | 2016-12-02 | 2020-01-16 | プロセナ バイオサイエンシーズ リミテッド | α−シヌクレインの二次構造プロファイルを検出する赤外線アッセイ |
| BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| KR102014066B1 (ko) | 2017-01-06 | 2019-10-21 | 에이비엘바이오 주식회사 | 항 α-syn 항체 및 그 용도 |
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| US11155608B2 (en) | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| BR112020011875A2 (pt) * | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| AU2019318195A1 (en) | 2018-08-09 | 2021-03-04 | F. Hoffmann-La Roche Ag | Determination of parkinson's disease |
| TWI734279B (zh) | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| CA3143242A1 (en) * | 2019-06-14 | 2020-12-17 | Abl Bio Inc. | Bispecific antibody against a-syn/igf1r and use thereof |
| CN115427443A (zh) | 2020-04-24 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 巯基化合物及其衍生物的酶和途径调节 |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| CN112710850A (zh) * | 2020-12-29 | 2021-04-27 | 苏州百志生物科技有限公司 | 一种检测人体液中α-突触核蛋白含量的试剂盒 |
| TWI824243B (zh) | 2021-05-05 | 2023-12-01 | 國立高雄大學 | 一種胜肽拓印導電聚合物及其用途 |
| CN113912712B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 抗α-突触核蛋白的单克隆抗体的制备及其应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| WO1996024369A1 (en) | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| AU2003299498A1 (en) | 2002-05-13 | 2004-05-25 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| WO2004065419A1 (ja) * | 2003-01-22 | 2004-08-05 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| US7022550B2 (en) | 2004-04-07 | 2006-04-04 | Gelcore Llc | Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| AR054428A1 (es) | 2005-03-08 | 2007-06-27 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina |
| US20080300204A1 (en) * | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| WO2007021255A1 (en) * | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| AU2006329963B2 (en) | 2005-12-06 | 2011-06-09 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| JP5558834B2 (ja) * | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| SI2126093T1 (sl) | 2007-03-02 | 2013-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Izboljšanje priprave proteinov |
| WO2008116103A2 (en) | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| RU2500686C2 (ru) * | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| DK2234600T3 (da) | 2007-12-21 | 2014-09-08 | Hoffmann La Roche | Antistofformulering |
| ES2544679T3 (es) | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Tratamiento y profilaxis de la amiloidosis |
| JP5747414B2 (ja) * | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| EP3521309A1 (en) * | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| PL214940B1 (pl) | 2009-07-31 | 2013-09-30 | Lozano Platonoff Alberto | Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
| EP2366714A1 (en) * | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
| CA2805112A1 (en) | 2010-07-15 | 2012-01-19 | Synovex Corporation | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| JP6023715B2 (ja) | 2010-10-11 | 2016-11-09 | アッヴィ・バハマズ・リミテッド | タンパク質の精製方法 |
| WO2012109280A2 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
| US8619359B2 (en) | 2011-04-27 | 2013-12-31 | Howard Letovsky | Electronic microscope filter |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| BR112013030472A2 (pt) | 2011-06-30 | 2019-09-24 | Genentech Inc | formulação farmacêutica, artigo de fabricação e método |
| PE20191242A1 (es) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
| HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
| LT3091029T (lt) | 2011-10-31 | 2023-02-27 | F. Hoffmann-La Roche Ag | Anti-il13 antikūno kompozicijos |
| CN108517010A (zh) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | 识别α-突触核蛋白的人源化抗体 |
| KR20190121874A (ko) | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2012
- 2012-10-26 HU HUE12844433A patent/HUE037811T2/hu unknown
- 2012-10-26 PL PL12844433T patent/PL2771031T3/pl unknown
- 2012-10-26 SM SM20230048T patent/SMT202300048T1/it unknown
- 2012-10-26 PL PL18155441.1T patent/PL3378535T3/pl unknown
- 2012-10-26 ES ES12844433.8T patent/ES2669395T3/es active Active
- 2012-10-26 SM SM20180307T patent/SMT201800307T1/it unknown
- 2012-10-26 RU RU2016101137A patent/RU2743738C2/ru active
- 2012-10-26 ES ES18155441T patent/ES2937409T3/es active Active
- 2012-10-26 SI SI201231300T patent/SI2771031T1/en unknown
- 2012-10-26 CN CN201711166162.2A patent/CN107880123A/zh active Pending
- 2012-10-26 MY MYPI2014001215A patent/MY165038A/en unknown
- 2012-10-26 RS RS20230054A patent/RS63930B1/sr unknown
- 2012-10-26 PE PE2014000613A patent/PE20141568A1/es not_active Application Discontinuation
- 2012-10-26 AU AU2012328530A patent/AU2012328530A1/en not_active Abandoned
- 2012-10-26 WO PCT/US2012/062290 patent/WO2013063516A1/en not_active Ceased
- 2012-10-26 DK DK18155441.1T patent/DK3378535T5/da active
- 2012-10-26 CN CN201280053194.0A patent/CN104334184B/zh active Active
- 2012-10-26 HR HRP20180728TT patent/HRP20180728T1/hr unknown
- 2012-10-26 KR KR1020147014374A patent/KR101600733B1/ko active Active
- 2012-10-26 LT LTEP12844433.8T patent/LT2771031T/lt unknown
- 2012-10-26 HU HUE18155441A patent/HUE061978T2/hu unknown
- 2012-10-26 RS RS20180539A patent/RS57315B1/sr unknown
- 2012-10-26 UA UAA201405767A patent/UA116194C2/uk unknown
- 2012-10-26 SG SG11201401857WA patent/SG11201401857WA/en unknown
- 2012-10-26 CA CA2853531A patent/CA2853531C/en active Active
- 2012-10-26 PH PH1/2014/500938A patent/PH12014500938B1/en unknown
- 2012-10-26 BR BR112014010198-1A patent/BR112014010198B1/pt active IP Right Grant
- 2012-10-26 EP EP12844433.8A patent/EP2771031B1/en active Active
- 2012-10-26 PT PT128444338T patent/PT2771031T/pt unknown
- 2012-10-26 HR HRP20230065TT patent/HRP20230065T1/hr unknown
- 2012-10-26 US US13/662,261 patent/US8609820B2/en active Active
- 2012-10-26 SI SI201232020T patent/SI3378535T1/sl unknown
- 2012-10-26 JP JP2014539089A patent/JP5775974B2/ja active Active
- 2012-10-26 FI FIEP18155441.1T patent/FI3378535T3/fi active
- 2012-10-26 EP EP18155441.1A patent/EP3378535B1/en active Active
- 2012-10-26 PT PT181554411T patent/PT3378535T/pt unknown
- 2012-10-26 LT LTEP18155441.1T patent/LT3378535T/lt unknown
- 2012-10-26 DK DK12844433.8T patent/DK2771031T3/en active
- 2012-10-26 MX MX2014005038A patent/MX370234B/es active IP Right Grant
-
2014
- 2014-01-15 US US14/156,441 patent/US9556259B2/en active Active
- 2014-04-25 CL CL2014001073A patent/CL2014001073A1/es unknown
- 2014-04-25 MX MX2019014658A patent/MX2019014658A/es unknown
- 2014-04-27 IL IL232264A patent/IL232264B/en active IP Right Grant
- 2014-05-26 CO CO14113186A patent/CO7020875A2/es unknown
- 2014-05-27 ZA ZA2014/03864A patent/ZA201403864B/en unknown
-
2015
- 2015-07-06 JP JP2015135643A patent/JP5960328B2/ja active Active
-
2016
- 2016-04-26 AU AU2016202622A patent/AU2016202622B2/en active Active
- 2016-06-22 JP JP2016123524A patent/JP6234511B2/ja active Active
- 2016-12-21 US US15/387,580 patent/US9884906B2/en active Active
-
2017
- 2017-10-24 JP JP2017205366A patent/JP6592059B2/ja active Active
- 2017-12-14 AU AU2017276296A patent/AU2017276296B2/en active Active
- 2017-12-28 US US15/857,104 patent/US10450369B2/en active Active
-
2018
- 2018-07-03 CY CY20181100693T patent/CY1120398T1/el unknown
- 2018-09-21 HK HK18112242.1A patent/HK1252895A1/zh unknown
-
2019
- 2019-05-20 US US16/417,309 patent/US10723792B2/en active Active
-
2020
- 2020-02-12 IL IL272615A patent/IL272615B/en unknown
- 2020-06-16 US US16/903,271 patent/US11345749B2/en active Active
-
2022
- 2022-04-26 US US17/730,074 patent/US12528858B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001073A1 (es) | Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy. | |
| CY2023014I1 (el) | Αντι il-36r αντισωματα | |
| DK3653645T3 (da) | Monoklonal interleukin-31-antistof | |
| DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| HUE036663T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| HUE036664T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| BR112014013034A2 (pt) | método para produzir um anticorpo | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| BR112013022797A2 (pt) | anticorpos anti-ctla4 humanizados | |
| HRP20160484T1 (hr) | Životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
| IL243311A0 (en) | Novel antibody frameworks | |
| DK2807188T3 (da) | Humaniserede antistoffer, der genkender alpha-synuclein | |
| PL3071595T3 (pl) | Humanizowane przeciwciało przeciw kalikreinie-2 | |
| BR112014011900A2 (pt) | um método de purificação de anticorpo | |
| PL3088421T3 (pl) | Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej | |
| BR112016003196A2 (pt) | método para separar anticorpos biespecíficos | |
| EP2733382A4 (en) | TORQUE ROD | |
| BR112014008691A2 (pt) | anticorpos para cd1d | |
| BR112014025664A2 (pt) | Método para preparar composição de sal de alumínio | |
| LT2742068T (lt) | Nauji antikūnai prieš fosforilcholiną | |
| CO6841994A2 (es) | Anticuerpos | |
| FR2973145B1 (fr) | Atlas visuo-tactile. | |
| DOP2011000313A (es) | Anticuerpos especificos para caderin-17 |